Sci/Tech trending topics
1,450 results
Stifel Nicolaus downgraded shares of Dendreon (NASDAQ: DNDN) from a hold rating to a sell rating in a report issued on Thursday, TheFlyOnTheWall.com reports. Dendreon (NASDAQ: DNDN) traded down 4.27% on Thursday, hitting $3.81. Dendreon has a …Daily Political · ByTyrone Williams · 5/13/2013
mideasttime.com
Zacks reaffirmed their neutral rating on shares of Dendreon (NASDAQ: DNDN) in a report issued on Monday, Stock Ratings Network.com reports. They currently have a $4.25 target price on the stock. Zacks’ analyst wrote, “Dendreon’s first-quarter 2013 ...Zolmax News · 5/15/2013
Dendreon (NASDAQ: DNDN) was downgraded by analysts at Roth Capital to a “sell” rating in a research report issued to clients and investors on Thursday, StocKRatingsNetwork.com reports. DNDN has been the subject of a number of other recent …Daily Political · ByLatisha Jones · 5/9/2013
Stock Analysts’ ratings reiterations for Friday, May 10th: Amarin Co. plc (NASDAQ: AMRN) had its buy rating reissued by analysts ... Providence Resources Corp (LON: PVR) had its buy rating reiterated by analysts at Cantor Fitzgerald.Zolmax News · 5/10/2013
In order to become successful, you need to have information as it happens and understand how it plays out into future stock price. This is our expertise ... d=2013-05-15&s=JNJ-MGM-DNDN-AGNC Johnson & Johnson (NYSE: JNJ) Did you want to hear …NBC News · 5/15/2013
Dendreon (NASDAQ: DNDN) had its price target decreased by Maxim Group from $4.00 to $3.00 in a research report released on Thursday morning, Analyst Ratings Network reports. Maxim Group currently has a sell rating on the stock. A number of other …mideasttime.com · 5/13/2013
Dendreon Corporation (NASDAQ:DNDN) stock plunged to record low in 9 months after the maker of the prostate cancer drug Provenge failed to meet Wall Street revenue forecasts. The Seattle-based Dendreon announced in a statement on Thursday that …SBWire · 5/10/2013
Biotechnology companies have been increasing competition from generic drug makers as patents on several blockbuster drugs continue to expire. In 2013 alone, patents on drugs with annual sales of nearly $30 billion are set to expire. For biotechnology ...Stockhouse · 5/8/2013
So far today, LPSN has been cut to "perform" from "outperform" at Oppenheimer, and had its rating lowered to "underperform" from "neutral" at Credit Suisse. What's more, price-target cuts have rolled in from analysts at Benchmark, Northland, Raymond …Schaeffer's Investment Research · ByElizabeth Harrow · 5/9/2013
New York, NY -- (SBWIRE) -- 05/09/2013 -- Dendreon Corporation (NASDAQ:DNDN) is a medical organization whose objective is to focus on cancer and convert lifestyles through the development, development, commercialization and production of novel …SBWire · 5/9/2013
- © 2013 Microsoft |
- Privacy and Cookies |
- Legal |
- Advertise |
- About our ads |
- Help |
- Feedback